OXALIPLATIN HOSPIRA 5 MG/ML
Country: Israel
Language: English
Source: Ministry of Health
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
OXALIPLATIN 5 MG/ML
Available from:
NOVAPHARMA LTD
ATC code:
L01XA03
Pharmaceutical form:
CONCENTRATE FOR SOLUTION FOR INFUSION
Administration route:
I.V
Manufactured by:
HOSPIRA UK LTD
Therapeutic group:
OXALIPLATIN
Therapeutic indications:
In combination with 5- fluorouracil and folinic acid (FA) oxaliplatin is indicated for: - adjuvant treatment of stage III ( Duke's C) colon cancer after complete resection of primary tumour - the treatment of metastatic colorectal cancer.
Authorization date:
2012-06-01
